Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.

Our results show that addition of biological parameters to previous prognostic indices improves patient stratification among patients treated with BTK inhibitor triplet combination, particularly, in the identification of an extreme high risk group.